Abstract:Abstract Background Tumor heterogeneity is contributed by tumor cells and the microenvironment. Dynamics of tumor heterogeneity during colorectal cancer (CRC) progression have not been elucidated. Methods Eight single-cell RNA sequencing (scRNA-seq) data sets of CRC were included. Milo was utilized to reveal the differential abundance of cell clusters during progression. The differentiation trajectory was imputed by using the Palantir algorithm and metabolic states were assessed by using scMetabolism. Three spatial transcription sequencing (ST-seq) data sets of CRC were used to validate cell-type abundances and colocalization. Cancer-associated regulatory hubs were defined as communication networks affecting tumor biological behaviors. Finally, quantitative reverse transcription polymerase chain reaction and immunohistochemistry staining were performed for validation. Results TM4SF1+, SOX4+, and MKI67+ tumor cells; CXCL12+ cancer-associated fibroblasts; CD4+ resident memory T cells; Treg; IgA+ plasma cells; and several myeloid subsets were enriched in stage IV CRC, most of which were associated with overall survival of patients. Trajectory analysis indicated that tumor cells from patients with advanced-stage CRC were less differentiated, when metabolic heterogeneity showed a highest metabolic signature in terminal states of stromal cells, T cells, and myeloid cells. Moreover, ST-seq validated cell-type abundance in a spatial context and also revealed the correlation of immune infiltration between tertiary lymphoid structures and tumors followed by validation in our cohort. Importantly, analysis of cancer-associated regulatory hubs revealed a cascade of activated pathways including leukocyte apoptotic process, MAPK pathway, myeloid leukocyte differentiation, and angiogenesis during CRC progression. Conclusions Tumor heterogeneity was dynamic during progression, with the enrichment of immunosuppressive Treg, myeloid cells, and fibrotic cells. The differential state of tumor cells was associated with cancer staging. Assessment of cancer-associated regulatory hubs suggested impaired antitumor immunity and increased metastatic ability during CRC progression.

[Colorectal Cancer Heterogeneity: Genotype, Phenotype and Clinical Manifestation].

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Heterogeneity Between Primary Colon Carcinoma and Paired Lymphatic and Hepatic Metastases.

Heterogeneity in Primary Colorectal Cancer and Its Corresponding Metastases: a Potential Reason of EGFR-targeted Therapy Failure?

Bladder Tumor Heterogeneity: The Impact on Clinical Treatment

Clinical management of breast cancer heterogeneity

Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes

Heterogeneity of the tumor immune microenvironment and its clinical relevance

A narrative review of tumor heterogeneity and challenges to tumor drug therapy

Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment

Biological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite

The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness

Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications

Clinical implications of intratumor heterogeneity: challenges and opportunities

Systems Heterogeneity: an Integrative Way to Understand Cancer Heterogeneity.

From tumour heterogeneity to advances in precision treatment of colorectal cancer

Dynamic heterogeneity of colorectal cancer during progression revealed clinical risk-associated cell types and regulations in single-cell resolution and spatial context

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

Heterogeneity within molecular subtypes of breast cancer

A physical mechanism of heterogeneity in stem cell, cancer and cancer stem cell

A quantitative tumor–wide analysis of morphological heterogeneity of colorectal adenocarcinoma